Acute myeloid leukemia (AML) remains one of the greatest challenges in hematology. Despite established chemotherapy protocols, the prognosis for many patients remains unfavorable. In recent years, however, new molecular classifications, refined risk stratification and the use of targeted substances have decisively changed treatment. The current overview summarizes the most important diagnostic, prognostic and therapeutic developments and provides oncologists with an evidence-based foundation for clinical practice in 2025.
Dieser Inhalt ist nur für Benutzer der Gruppe: Medizinische Fachperson zugänglich
Jetzt beitreten
Jetzt beitreten
Already a member? Log in here
